Opthea/$OPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Opthea
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.
Ticker
$OPT
Sector
Primary listing
Employees
33
Headquarters
Melbourne, Australia
Website
Opthea Metrics
BasicAdvanced
$544M
-
-$0.13
1.47
-
Price and volume
Market cap
$544M
Beta
1.47
52-week high
$6.30
52-week low
$3.03
Average daily volume
39K
Financial strength
Current ratio
0.22
Quick ratio
0.217
Total debt to equity
-122.84
Interest coverage (TTM)
-3.18%
Profitability
EBITDA (TTM)
-147.761
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-111,500.68%
Operating margin (TTM)
-106,686.30%
Effective tax rate (TTM)
4.09%
Management effectiveness
Return on assets (TTM)
-75.21%
Return on equity (TTM)
117.59%
Valuation
Price to revenue (TTM)
28,655.462
Price to book
-3.67
Price to tangible book (TTM)
-3.67
Price to free cash flow (TTM)
-26.322
Free cash flow yield (TTM)
-3.80%
Free cash flow per share (TTM)
-0.13
Growth
Revenue change (TTM)
-44.24%
Earnings per share change (TTM)
-61.48%
3-year revenue growth (CAGR)
-9.81%
10-year revenue growth (CAGR)
-9.10%
3-year earnings per share growth (CAGR)
-20.45%
10-year earnings per share growth (CAGR)
15.33%
What the Analysts think about Opthea
Analyst ratings (Buy, Hold, Sell) for Opthea stock.
Opthea Financial Performance
Revenues and expenses
Opthea Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Opthea stock?
Opthea (OPT) has a market cap of $544M as of September 18, 2025.
What is the P/E ratio for Opthea stock?
The price to earnings (P/E) ratio for Opthea (OPT) stock is 0 as of September 18, 2025.
Does Opthea stock pay dividends?
No, Opthea (OPT) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Opthea dividend payment date?
Opthea (OPT) stock does not pay dividends to its shareholders.
What is the beta indicator for Opthea?
Opthea (OPT) has a beta rating of 1.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.